LENZ Therapeutics, Inc. (LENZ)

Corporate Overview

LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia.

Our Leadership

Latest Financial Results

Q1 2025

Quarter Ended Mar 31, 2025

Earnings Release PDF

Earnings Webcast

10-Q PDF

XBRL

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Latest News

May 9, 2025 • 9:03 AM EDT

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

View Press Release View All News

Upcoming Event

May 13, 2025 9:20 am PDT

BofA Securities 2025 Health Care Conference

View Event Add to Calendar View All Events

Email Alerts

Get the latest news and reports delivered right to your inbox.

IR Contacts

Corporate

LENZ Therapeutics, Inc.
201 Lomas Santa Fe Drive
Suite 300
Solana Beach, CA 92075
T: (888) 928-LENZ (5369)
contact@lenz-tx.com

Investor Relations

LENZ Therapeutics
IR@LENZ-Tx.com

Transfer Agent

Equiniti Trust Company, LLC
48 Wall Street
New York, NY 10005
T: 800-937-5449